Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Letter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
Bias/Fraud | Business of Medicine | Children Victimized | Corrupt Practices | Fraud | Psych Drugs | Research Integrity
Pharma Spin and Child Suicide Rates
Today's news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
Pharma Spin Childhood Suicide Rates
Today’s news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
Psychiatry News: High Cost of Nondisclosure
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
Medicine In Conflict:Financial Tentacles in Cardiology_Business Week
Business Week reports: "From 1986 to 2003 the number of nonsurgical cardiac procedures, such as propping open arteries with wire-mesh stents, rose twelve fold, according to the American Heart Association.
Follow the Money / Can the Institute of Medicine Review the FDA?
Follow the Money / Can the Institute of Medicine Review the FDA? Wed, 6 Apr 2005 A letter to the editor published in Nature Medicine by Dr. Bernard Carroll, a past chairman of the FDA Advisory Committee for Psychotropic Drugs, and past chairman of the Department of Psychiatry at Duke…
Doctors Without Borders: Why you can’t trust medical journals anymore
Doctors Without Borders: Why you can’t trust medical journals anymore Tue, 13 Apr 2004 Related link: Hear an interview with Shannon Brownlee on NPR at: http://www.npr.org/features/feature.php?wfId=1874563 Doctors Without Borders in the Washington Monthly (excerpt below), looks at the intricate web of collaborating players in medicine who are financially tied one…
Relapse Producing Experiments – a Partial Bibliography
<spanstyle=’font-size:11.0pt;font-family:Arial’>FEDERALLY-FUNDED RELAPSE PRODUCING EXPERIMENTS in PSYCHIATRY: DRUG WASHOUT / CHEMICAL PROVOCATION<spanstyle=’font-size:11.0pt;font-family:Arial’> <spanstyle=’font-size:11.0pt;font-family:Arial’>A PARTIAL BIBLIOGRAPHY (Jan 2000) <spanstyle=’font-size:11.0pt;font-family:Arial’>By VERA HASSNER SHARAV Experiments such as those listed below have no diagnostic or therapeutic purpose: They are conducted often on disabled veterans to test speculative, unproven theories. National Institute of Mental Health:<spanstyle=’font-size:11.0pt;font-family:Arial’>…
Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ
Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ Thu, 19 May 2005 Another major scandal is erupting about FDA’s approval decisions that contradict its medical officer’s safety concerns. The Senate Finance Committee is investigating what led the FDA to suddenly reverse its disapproval of Cyberonics’ brain stimulation…
2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…